Roivant Sciences Ltd.
Close on Nov 18, 2026Market cap $27.98BP/E –Yield –
Roivant Sciences Total Program-Specific R&D Expense by Quarter
Total Program-Specific R&D Expense ($M)
Roivant Sciences Total Program-Specific R&D Expense: $96.8M in Q2 FY2026, down 6.2% from a year earlier.
Where the Q2 FY2026 figure comes from
“|| Total program-specific costs | 96,817 | 103,230 | (6,413)”
Source: Form 10-Q (roiv-20260930.htm, filed 2026-11-09) ↗
Reported in Form 10-K / 10-Q (MD&A & Segment Footnote).
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total Program-Specific R&D Expense
- Anti-FcRn Franchise — Endocrine Diseases R&D22.5 · Q2 FY2026
- Anti-FcRn Franchise — Neurological Diseases R&D18.3 · Q2 FY2026
- Anti-FcRn Franchise — Rheumatology Diseases R&D9.90 · Q2 FY2026
- Anti-FcRn Franchise — Dermatology Diseases R&D0.60 · Q2 FY2026
- Anti-FcRn Franchise — Other Clinical & Nonclinical R&D0.27 · Q2 FY2026
- Brepocitinib (LISRAYA) Program R&D14.4 · Q2 FY2026
- Mosliciguat Program R&D19.1 · Q2 FY2026
- Other Development & Discovery Programs R&D11.8 · Q2 FY2026
- Tapinarof (VTAMA) Program R&D (Legacy, Divested FY2024)6.96 · Q1 FY2024
- RVT-3101 (Telavant) Program R&D (Legacy, Divested FY2023)0 · Q3 FY2024
- Namilumab Program R&D (Legacy)3.13 · Q3 FY2024
- RVT-2001 Program R&D (Legacy)0.03 · Q3 FY2024
Cite this data
StockData. (2026). Roivant Sciences Total Program-Specific R&D Expense ($M), quarterly Q1 FY2020–Q2 FY2026 [Data set]. Compiled from Roivant Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/roiv/kpis/rd-program-total
See every metric in the Roivant Sciences KPI table. Data updated Nov 16, 2026.
See a number that looks wrong?